New advances in clinical management of candidemia

Chi Jung Wu, Hsin Chun Lee, Wen-Chien Ko

研究成果: Article

摘要

The overall incidence of candidemia has increased persistently Worldwide during the second half of the 20th century. This increase is the consequence of larger immunocompromised population resulting from their underlying disease, or from their immunosuppressive treatment or intensive care, such as total parenteral nutrition, and central venous catheter placement. The overall mortality of patients with candidemia is high. However, the yield rate of positive blood cultures for candidemia is less than 50%, even in patients with severe neutropenia or immunosuppression, in whom disseminated candidiasis is strongly suspected. Therefore, highly clinical suspicion in identifying patients in high risky groups is needed to guide empirical therapy. All candidemic patients should be treated and the delay in or lack of effective treatment is associated with a grave outcome. In clinical management of patients with candidemia, antifungal agents are used according to the severity of the disease and the causative Candida species. In addition to fluconazole and amphotericin B, the newly developed agents, such as voriconazole and caspofungin, both demonstrate a promising therapeutic efficacy. Whereas, the consensus about the fate of CVC in candidemia patients has not been achieved yet. PCR-based diagnostic strategy, which makes early diagnosis of candidemia possible, may be a new tool for preemptive therapy in febrile neutropenic patients.

原文English
頁(從 - 到)224-231
頁數8
期刊Journal of Internal Medicine of Taiwan
14
發行號5
出版狀態Published - 2003 十二月 1

指紋

Candidemia
caspofungin
Therapeutics
Central Venous Catheters
Total Parenteral Nutrition
Fluconazole
Candidiasis
Antifungal Agents
Amphotericin B
Critical Care
Immunosuppressive Agents
Neutropenia
Candida
Immunosuppression
Early Diagnosis
Fever
Polymerase Chain Reaction
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Internal Medicine

引用此文

Wu, Chi Jung ; Lee, Hsin Chun ; Ko, Wen-Chien. / New advances in clinical management of candidemia. 於: Journal of Internal Medicine of Taiwan. 2003 ; 卷 14, 編號 5. 頁 224-231.
@article{79aa9d7d8bdd4a36bde357594b83a491,
title = "New advances in clinical management of candidemia",
abstract = "The overall incidence of candidemia has increased persistently Worldwide during the second half of the 20th century. This increase is the consequence of larger immunocompromised population resulting from their underlying disease, or from their immunosuppressive treatment or intensive care, such as total parenteral nutrition, and central venous catheter placement. The overall mortality of patients with candidemia is high. However, the yield rate of positive blood cultures for candidemia is less than 50{\%}, even in patients with severe neutropenia or immunosuppression, in whom disseminated candidiasis is strongly suspected. Therefore, highly clinical suspicion in identifying patients in high risky groups is needed to guide empirical therapy. All candidemic patients should be treated and the delay in or lack of effective treatment is associated with a grave outcome. In clinical management of patients with candidemia, antifungal agents are used according to the severity of the disease and the causative Candida species. In addition to fluconazole and amphotericin B, the newly developed agents, such as voriconazole and caspofungin, both demonstrate a promising therapeutic efficacy. Whereas, the consensus about the fate of CVC in candidemia patients has not been achieved yet. PCR-based diagnostic strategy, which makes early diagnosis of candidemia possible, may be a new tool for preemptive therapy in febrile neutropenic patients.",
author = "Wu, {Chi Jung} and Lee, {Hsin Chun} and Wen-Chien Ko",
year = "2003",
month = "12",
day = "1",
language = "English",
volume = "14",
pages = "224--231",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "Society of Internal Medicine of Taiwan",
number = "5",

}

New advances in clinical management of candidemia. / Wu, Chi Jung; Lee, Hsin Chun; Ko, Wen-Chien.

於: Journal of Internal Medicine of Taiwan, 卷 14, 編號 5, 01.12.2003, p. 224-231.

研究成果: Article

TY - JOUR

T1 - New advances in clinical management of candidemia

AU - Wu, Chi Jung

AU - Lee, Hsin Chun

AU - Ko, Wen-Chien

PY - 2003/12/1

Y1 - 2003/12/1

N2 - The overall incidence of candidemia has increased persistently Worldwide during the second half of the 20th century. This increase is the consequence of larger immunocompromised population resulting from their underlying disease, or from their immunosuppressive treatment or intensive care, such as total parenteral nutrition, and central venous catheter placement. The overall mortality of patients with candidemia is high. However, the yield rate of positive blood cultures for candidemia is less than 50%, even in patients with severe neutropenia or immunosuppression, in whom disseminated candidiasis is strongly suspected. Therefore, highly clinical suspicion in identifying patients in high risky groups is needed to guide empirical therapy. All candidemic patients should be treated and the delay in or lack of effective treatment is associated with a grave outcome. In clinical management of patients with candidemia, antifungal agents are used according to the severity of the disease and the causative Candida species. In addition to fluconazole and amphotericin B, the newly developed agents, such as voriconazole and caspofungin, both demonstrate a promising therapeutic efficacy. Whereas, the consensus about the fate of CVC in candidemia patients has not been achieved yet. PCR-based diagnostic strategy, which makes early diagnosis of candidemia possible, may be a new tool for preemptive therapy in febrile neutropenic patients.

AB - The overall incidence of candidemia has increased persistently Worldwide during the second half of the 20th century. This increase is the consequence of larger immunocompromised population resulting from their underlying disease, or from their immunosuppressive treatment or intensive care, such as total parenteral nutrition, and central venous catheter placement. The overall mortality of patients with candidemia is high. However, the yield rate of positive blood cultures for candidemia is less than 50%, even in patients with severe neutropenia or immunosuppression, in whom disseminated candidiasis is strongly suspected. Therefore, highly clinical suspicion in identifying patients in high risky groups is needed to guide empirical therapy. All candidemic patients should be treated and the delay in or lack of effective treatment is associated with a grave outcome. In clinical management of patients with candidemia, antifungal agents are used according to the severity of the disease and the causative Candida species. In addition to fluconazole and amphotericin B, the newly developed agents, such as voriconazole and caspofungin, both demonstrate a promising therapeutic efficacy. Whereas, the consensus about the fate of CVC in candidemia patients has not been achieved yet. PCR-based diagnostic strategy, which makes early diagnosis of candidemia possible, may be a new tool for preemptive therapy in febrile neutropenic patients.

UR - http://www.scopus.com/inward/record.url?scp=0347286949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347286949&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0347286949

VL - 14

SP - 224

EP - 231

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 5

ER -